Elisa Conti

Dr. Elisa Conti

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2011 in Neurology
Verified
Journal Article
Closed access
PDF file
JDJacopo C. DiFrancesco
Jacopo C. DiFrancesco
MBM. Brioschi
M. Brioschi
LBL. Brighina
L. Brighina
CRC. Ruffmann
C. Ruffmann
ESE. Saracchi
E. Saracchi
CFC. Ferrarese
C. Ferrarese

13 November 2013 in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Verified
Journal Article
Closed access
PDF file
LTLucio Tremolizzo
Lucio Tremolizzo
PMPaolo Messina
Paolo Messina
ECElisa Conti
Elisa Conti
GSGessica Sala
Gessica Sala
MCMatteo Cecchi
Matteo Cecchi
FPFederica Edith Pisa
Federica Edith Pisa
ALS is a heterogeneous disease that is not well understood. Epigenetic rearrangements are important in complex disorders including motor neuron diseases. The aim of this study was to determine whether whole-blood DNA methylation (DNA MET %) is a potential modifier of age at onset in ALS. DNA MET % was measured as incorporation of [3H]dCTP following HpaII cut in 96 ALS patients and 87 controls, comprising: early-onset (< 55 years of age) and late-onset (> 74 years of age). Methionine (Met) and homocysteine (Hcy) plasma levels were assessed by liquid chromatography selected reaction monitoring coupled with isotope-dilution mass spectrometry. Results showed that DNA MET % was increased in ALS patients independently of age of onset. Compared to the other three groups, Hcy plasma levels were reduced in early-onset ALS patients but Met levels were similar. ROC analysis reported Met levels and DNA MET %, respectively, with a slight and moderate discriminative power. In conclusion, increased DNA MET % is a possible marker of epigenetic dysfunction in ALS independently of age of onset. Further studies dissecting biological determinants of phenotypic complexity in ALS may help in developing successful therapeutic strategies.

24 August 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
FAFederica Angiulli
Federica Angiulli
ECElisa Conti
Elisa Conti
CZChiara Paola Zoia
Chiara Paola Zoia
FRFulvio Da Re
Fulvio Da Re
IAIldebrando Appollonio
Ildebrando Appollonio
LTLucio Tremolizzo
Lucio Tremolizzo
Neuroinflammation represents a central feature in the development of Alzheimer’s disease (AD). The resident innate immune cells of the brain are the principal players in neuroinflammation, and their activation leads to a defensive response aimed at promoting β-amyloid (Aβ) clearance. However, it is now widely accepted that the peripheral immune system—by virtue of a dysfunctional blood–brain barrier (BBB)—is involved in the pathogenesis and progression of AD; microglial and astrocytic activation leads to the release of chemokines able to recruit peripheral immune cells into the central nervous system (CNS); at the same time, cytokines released by peripheral cells are able to cross the BBB and act upon glial cells, modifying their phenotype. To successfully fight this neurodegenerative disorder, accurate and sensitive biomarkers are required to be used for implementing an early diagnosis, monitoring the disease progression and treatment effectiveness. Interestingly, as a result of the bidirectional communication between the brain and the periphery, the blood compartment ends up reflecting several pathological changes occurring in the AD brain and can represent an accessible source for such biomarkers. In this review, we provide an overview on some of the most promising peripheral biomarkers of neuroinflammation, discussing their pathogenic role in AD.

29 November 2013 in The World Journal of Biological Psychiatry
Verified
Journal Article
Closed access
LTL. Tremolizzo
L. Tremolizzo
ECElisa Conti
Elisa Conti
MBM. Bomba
M. Bomba
OUO. Uccellini
O. Uccellini
MRM.S. Rossi
M.S. Rossi
RNR. Nacinovich
R. Nacinovich
The one-carbon metabolism, also known as methionine-homocysteine cycle, governs the dynamics of DNA methylation, epigenetically regulating gene expression, and has been reported altered in anorexia nervosa (AN) adult patients. The aim of this study consisted in assessing whole-blood DNA methylation in adolescent AN patients, assessing its significance in relationship to clinical and hormonal variables. Whole-blood global DNA methylation was measured as incorporation of [(3)H]dCTP following HpaII cut in 32 adolescent females affected by restrictive type AN and compared to 13 healthy controls. Homocysteine, vitamin B12 and folate plasma levels were assessed as well as fasting plasma levels of leptin and steroid hormones. Clinical variables, including severity and associate states and traits, were assessed by means of the EDI-3, CDI and STAI-Y scales. We confirm that whole-blood global DNA methylation is modestly albeit significantly reduced in AN adolescents with respect to controls, correlating with plasma leptin and steroid hormone levels. Conversely, clinical traits did not correlate with the outcome variable. A better definition of the epigenetic dysregulation underlying AN pathology or vulnerability might lead to develop useful markers for diagnosis, prognostic classification and tailored therapeutic interventions in these vulnerable patients since the earliest phases of their disease.

1 September 2017 in Neurochemistry International
Verified
Journal Article
Closed access
ECElisa Conti
Elisa Conti
MGMaria Gregori
Maria Gregori
IRIsabella Radice
Isabella Radice
FRFulvio Da Re
Fulvio Da Re
DGDenise Grana
Denise Grana
LTLucio Tremolizzo
Lucio Tremolizzo

29 November 2014 in International Journal of Eating Disorders
Verified
Journal Article
Closed access
PDF file
FCFabiola Corbetta
Fabiola Corbetta
LTLucio Tremolizzo
Lucio Tremolizzo
ECElisa Conti
Elisa Conti
CFCarlo Ferrarese
Carlo Ferrarese
FNFrancesca Neri
Francesca Neri
RNRenata Nacinovich
Renata Nacinovich